0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Case Report/Case Series |

COX10 Mutations Resulting in Complex Multisystem Mitochondrial Disease That Remains Stable Into Adulthood

Robert D. S. Pitceathly, MRCP1; Jan-Willem Taanman, PhD2; Shamima Rahman, PhD1,3; Brigitte Meunier, PhD4; Michael Sadowski, PhD5; Sebahattin Cirak, PhD6; Iain Hargreaves, PhD7; John M. Land, PhD7; Tina Nanji, BSc8; James M. Polke, PhD8; Cathy E. Woodward, BSc8; Mary G. Sweeney, BSc8; Shyam Solanki, BSc2; A. Reghan Foley, MD6; Matthew E. Hurles, PhD9; Jim Stalker, MA9; Julian Blake, MRCP10,11; Janice L. Holton, PhD1,12; Rahul Phadke, FRCPath6,12; Francesco Muntoni, MD6; Mary M. Reilly, FRCP1,13; Michael G. Hanna, FRCP1,13 ; for the UK10K Consortium
[+] Author Affiliations
1Medical Research Council Centre for Neuromuscular Diseases, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, England
2Department of Clinical Neuroscience, University College London Institute of Neurology, London, England
3Mitochondrial Research Group, Clinical and Molecular Genetics Unit, University College London Institute of Child Health, London, England
4Centre de Génétique Moléculaire, UPR3404, Centre national de la recherche scientifique, Gif-sur-Yvette, France
5Division of Mathematical Biology, National Institute for Medical Research, London, England
6Dubowitz Neuromuscular Centre, University College London Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, London, England
7Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, London, England
8Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, England
9The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, England
10Department of Clinical Neurophysiology, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, England
11Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich, England
12Division of Neuropathology, University College London Institute of Neurology, London, England
13Department of Molecular Neuroscience, University College London Institute of Neurology, London, England
JAMA Neurol. 2013;70(12):1556-1561. doi:10.1001/jamaneurol.2013.3242.
Text Size: A A A
Published online

Importance  Isolated cytochrome-c oxidase (COX) deficiency is one of the most frequent respiratory chain defects seen in human mitochondrial disease. Typically, patients present with severe neonatal multisystem disease and have an early fatal outcome. We describe an adult patient with isolated COX deficiency associated with a relatively mild clinical phenotype comprising myopathy; demyelinating neuropathy; premature ovarian failure; short stature; hearing loss; pigmentary maculopathy; and renal tubular dysfunction.

Observations  Whole-exome sequencing detected 1 known pathogenic and 1 novel COX10 mutation: c.1007A>T; p.Asp336Val, previously associated with fatal infantile COX deficiency, and c.1015C>T; p.Arg339Trp. Muscle COX holoenzyme and subassemblies were undetectable on immunoblots of blue-native gels, whereas denaturing gels and immunocytochemistry showed reduced core subunit MTCO1. Heme absorption spectra revealed low heme aa3 compatible with heme A:farnesyltransferase deficiency due to COX10 dysfunction. Both mutations demonstrated respiratory deficiency in yeast, confirming pathogenicity. A COX10 protein model was used to predict the structural consequences of the novel Arg339Trp and all previously reported substitutions.

Conclusions and Relevance  These findings establish that COX10 mutations cause adult mitochondrial disease. Nuclear modifiers, epigenetic phenomenon, and/or environmental factors may influence the disease phenotype caused by reduced COX activity and contribute to the variable clinical severity related to COX10 dysfunction.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.
Results of Sural Nerve Biopsy, Electron Microscopy, and Muscle Biopsy

A, Sural nerve biopsy specimen. High-magnification view of one fascicle (semithin section of resin stained with methylene blue-azure basic fuchsin) shows moderate depletion of myelinated fibers with several large diameter axonal profiles displaying inappropriately thin myelin sheaths for their diameter, suggesting demyelination (A [arrowheads]). Electron microscopy demonstrates 2 examples of demyelinating axons (B and C) and tightly packed inclusions within a myelinated fiber Schwann cell cytoplasm (D [asterisk]). E, Inspection at higher magnification shows membrane-bound filamentous inclusions (asterisks) closely associated with the Golgi cisternae (arrowheads). F, Muscle biopsy specimen shows decreased COX staining in the majority of fibers. Ragged-red fibers were not present. Scale bars represent 100 μm.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Immunoblot Analysis, Immunocytochemical Micrographs, and Muscle Heme Absorption Spectra

Immunoblot analysis of blue-native (A) and sodium dodecyl sulfate (B) polyacrylamide gels loaded with mitochondrial membrane proteins extracted from muscle. A, The cytochrome-c oxidase (COX) holoenzyme was undetectable in the patient (P), unlike the controls (C1-3). B, The COX10 protein steady state levels were normal in the patient compared with the controls, indicating that the COX10 missense mutations do not impair COX10 protein stability, whereas MTCO1 was undetectable in the patient, unlike the controls. C, Micrographs of a control’s and the patient’s fibroblasts are shown immunocytochemically stained for MTCO1 (green fluorescence) and MitoTracker Red (Life Technologies; red fluorescence), and counterstained with the DNA fluorochrome 4′,6-diamidino-2-phenylindole (blue fluorescence); the patient’s cells show a general decrease in MTCO1 levels compared with the control’s cells. D, Air-oxidized vs sodium dithionite–reduced heme spectra of the patient’s muscle mitochondrial proteins are shown. There is loss of the heme aa3 γ band at 445 nm (D [arrowhead]) in the patient compared with the control. MW indicates molecular weight.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Growth of Yeast on a Nonfermentable Carbon Source and Hypothetical COX10 Protein Model

Growth of COX10 p.Asp336Val, COX10 p.Arg339Trp and COX10 Asp336Val plus Arg339Trp yeast strains and a control on glucose (A) and glycerol/ethanol (B) as carbon source. Both COX10 mutations cause respiratory deficiency, as demonstrated by the impaired growth on the nonfermentable carbon source glycerol/ethanol. When both mutations coexisted, the respiratory deficiency appeared to be even more pronounced (A and B). C, A topology diagram of the COX10 protein shows locations of both known and the herein reported mutated COX10 residues highlighted in red; the transmembrane segments are labeled with Roman numerals (I-IX). A structural model of COX10 shows the locations of residues 336, 339, and 225 (D) and residues 196, 204, 225, 336, and 339 looking up from the mitochondrial matrix at the putative face of the bundle (E). COOH indicates the C-terminus (also known as the carboxyl terminus) of the protein; and H2N, the N-terminus (also known as the amino terminus) of the protein.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();